Clinical Trials in Phoenix

Showing 6241-6260 of 16,646 trials

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

NCT04599972

This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.

Presbyopia

Orasis Pharmaceuticals Ltd.304 participantsStarted Oct 2020

Chandler, Arizona, United States • Mesa, Arizona, United States • Phoenix, Arizona, United States +15 more locations

SUSPENDEDPhase 3< 1 mile

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

NCT02546102

ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to evaluate ICT-107 in patients with newly diagnosed glioblastoma. Subjects will be randomized to receive standard of care chemoradiation (temozolomide (TMZ) with either ICT-107 or a blinded control. Reinfusion with the pulsed dendritic cells should stimulate cytotoxic T cells to specifically target glioblastoma tumour cells.

Glioblastoma Multiforme

Precision Life Sciences Group234 participantsStarted Dec 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Duarte, California, United States +62 more locations

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Find Trials by Condition in Phoenix

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

Spiration Valves Against Standard Therapy

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers